New drugs up for approval
January 28, 2011
NINE new drugs are up for
consideration as new medicines to
be added to the Schedule of
Pharmaceutical Benefits, according
to the PBAC meeting agenda for
March 2011 released yesterday.
Included in the line-up are:
Movetro (cladribine) 10mg tablet
for the treatment of MS; Tadim
(colistimethate sodium powder) for
nebuliser solution, 1 million IU
(equivalent to 80 mg
colistimethate sodium), for the
treatment of lung infections in
patients with cystic fibrosis; and
Gilenya (finigolimod) capsule
0.5mg (as hydrochloride) for MS.
Other submissions include
Bronchitol (mannitol) capsule
containing powder for oral
inhalation 40mg, for cystic fibrosis;
Lyrica (pregabalin) capsules 25mg,
75mg, 150mg and 300mg for
neuropathic pain; Serdolect
(sertindole) tablets 4mg, 12mg,
16mg and 20mg for
schizophrenia; Palexia SR
(tapentadol hydrochloride) tablets
50mg, 100mg, 150mg, 200mg
abd 250mg (as hydrochloride) for
severe pain; and Twynsta
(telmisartan with amlodipine) 40
mg–5 mg, 40 mg–10 mg, 80 mg–
5 mg and 80 mg–10 mg (as
besylate) as an antihypertensive;
and Zolinza (vorinostat) capsule
100mg anti-cancer drug.
Also up for consideration are six
new drug applications (for
Suboxone, Docetaxel Actavis,
Denpax, Ferro-Tab, Emend IV, and
Oratane) relating to new forms of
previously listed drugs and
changes to conditions of use.
The new drug submissions are
currently up for public comment
until 09 February- www.pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jan 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jan 11
